Ecospirin (aspirin, Enteric-Coated)

# Ecospirin (aspirin, Enteric-Coated) ## Overview Ecospirin is a cyclooxygenase (COX) inhibitor that provides irreversible inhibition of platelet aggregation by blocking thromboxane A2 production. The enteric coating is designed to reduce direct gastric mucosal irritation, though it does not eliminate the risk of systemic gastrointestinal ulceration. ## Primary Indications * Secondary prevention of myocardial infarction (MI) and ischemic stroke. * Acute coronary syndromes (ACS). * Management of stable/unstable angina. * Prevention of transient ischemic attacks (TIA). ## Adult Dosing * **Acute Coronary Syndrome:** 162–325 mg (non-enteric coated preferred for initial loading dose if possible, otherwise chewed/crushed). * **Secondary Prevention (Maintenance):** 75–162 mg once daily. * **Dosing Note:** Local institutional protocols may vary; maintenance doses of 81 mg are standard in many regions, while some clinicians prefer higher doses for specific cardiovascular indications. ## Pediatric Dosing * **Kawasaki Disease (Acute Phase):** 80–100 mg/kg/day in 4 divided doses. * **Antiplatelet:** 3–5 mg/kg/day once daily. * **Note:** Use in children is restricted due to the high risk of Reye's syndrome following viral infections (e.g., influenza, varicella). ## Dose Adjustments * **Renal Impairment:** Use with caution in severe impairment (CrCl <10 mL/min); dosage adjustments not strictly defined, but risk of toxicity increases. * **Hepatic Impairment:** Avoid or use with extreme caution in severe liver disease due to altered metabolism and bleeding risk. ## Contraindications * Hypersensitivity to salicylates or NSAIDs. * Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage). * Asthma associated with "aspirin triad" (asthma, nasal polyps, aspirin sensitivity). * Pediatric patients with viral infections (risk of Reye's syndrome). ## Adverse Effects * **Gastrointestinal:** Dyspepsia, nausea, abdominal pain, occult blood loss, gastric ulceration. * **Hematologic:** Increased risk of bleeding, prolonged bleeding time. * **Dermatologic:** Urticaria, rash. * **Other:** Tinnitus (sign of salicylate toxicity), bronchospasm. ## Key Drug Interactions * **NSAIDs (e.g., Ibuprofen):** May interfere with the antiplatelet effect of low-dose aspirin; space doses if necessary. * **Anticoagulants (e.g., Warfarin, DOACs) & Antiplatelets (e.g., Clopidogrel):** Significant increase in bleeding risk. * **Corticosteroids:** Increased risk of GI ulceration. * **Alcohol:** Increases risk of GI mucosal injury. ## Monitoring * **Clinical:** Watch for signs of overt or occult bleeding (melena, hematuria, bruising). * **Laboratory:** Monitor hemoglobin/hematocrit if long-term therapy is used. * **Toxicity:** Monitor for tinnitus or altered mental status in elderly patients or high-dose therapy. ## Clinical Pearls * **Absorption:** Enteric coating delays absorption; in acute MI, non-enteric coated aspirin is preferred for faster onset. If only enteric-coated is available, chew the tablet to hasten absorption. * **Surgery:** Generally held 5–7 days prior to elective surgery depending on the procedure's bleeding risk and the indication for aspirin. * **Compliance:** Stress the importance of daily adherence for secondary cardiovascular prevention. *** *Disclaimer: This information is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always verify prescribing information with the latest institutional guidelines, the Summary of Product Characteristics (SmPC), or the drug manufacturer's official labeling before administration.*